BIOIMAGING

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 该核心设计用于提供定量磁共振成像(MRI)、体积定位光谱(MRS)、光谱成像(MRSI)和单光子发射计算机断层扫描(SPECT)，用于体内分析细胞和纳米材料的生物分布和治疗效果。项目支助包括纳米材料分布的药代动力学测量(项目1-4)、超顺磁性氧化铁标记细胞的T2*加权成像(项目3)和纳米材料(提高灵敏度和空间分辨率的替代方法，项目1、3、4)或伽马标记纳米颗粒的SPECT(项目1、3、4)和细胞(项目1)。疾病进展和治疗结果的非侵入性监测将通过使用T1和T2加权MRI(项目3，4)观察肿瘤大小，使用自旋标记灌注MRI(项目4)观察肿瘤灌流，以及通过31P MRS(未来发展，项目3，4和未来肿瘤纳米材料开发项目)早期确定药物疗效来提供。监测神经元活性、神经毒性和/或疾病进展将使用定量水抑制质子磁共振波谱成像(1H MRSI)来完成(项目1、2、3)。虽然划分是为了将核心结构分为药物监测和疾病监测，但目标是根据技术方法划分的。这样做的目的是最好地说明将如何利用核心及其重要的技术资源。显然，执行SPECT、各种定量MRI方法、1H MRSI和31P MRS以支持纳米医学中广泛的研究活动的能力是这一提议的关键优势。这一核心将提供精确定义药物生物分布、吸收动力学的能力，为基于靶向纳米颗粒的新造影剂的开发提供支持，重要的是，纳米材料药物输送对疾病结果的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. This core is designed to provide quantitative magnetic resonance imaging (MRI), volume localized spectroscopy (MRS), spectroscopic imaging (MRSI) and single photon emission computed tomography (SPECT) for in-vivo assays of cell and nanomaterial biodistribution and treatment efficacy. Project support includes pharmacokinetic measures of nanomaterial distribution (Projects 1-4), T2* weighted imaging of superparamagnetic iron oxide labeled cells (Project 3) and nanomaterials (alternate method for improved sensitivity and spatial resolution, Projects 1, 3, 4) or SPECT of gamma labeled nanoparticles (Projects 1, 3, 4) and cells (Project 1). Non-invasive monitoring of disease progression and therapeutic outcomes will be provided by observing tumor size using T1 and T2 weighted MRI (Projects 3,4), tumor perfusion using spin tagged perfusion MRI (Project 4), and early determination of drug efficacy by 31P MRS (Future development, Projects 3,4 and future tumor nanomaterial development projects). Monitoring neuronal viability, neurotoxicity, and/or disease progression will be accomplished using quantitative water-suppressed proton magnetic resonance spectroscopic imaging (1H MRSI) (Projects 1, 2, 3). Although the divisions were made to separate the core structures into drug and disease monitoring, the aims are divided based on technical approaches. This was done with the goals of best describing how the core and its significant technical resources will be utilized. Clearly, the abilities to perform SPECT, a variety of quantitative MRI methods, 1H MRSI, and 31P MRS to support broad based research activities in nanomedicine are critical strengths of this proposal. This core will provide abilities to precisely define drug biodistribution, uptake kinetics, provide support for development of new contrast agents based on targeted nanoparticles, and importantly, affects of nanomaterial drug delivery on disease outcomes.